Literature DB >> 11753383

The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH.

Laurent Gouya1, Herve Puy, Anne-Marie Robreau, Monique Bourgeois, Jerôme Lamoril, Vasco Da Silva, Bernard Grandchamp, Jean-Charles Deybach.   

Abstract

Erythropoietic protoporphyria (EPP) is an inherited disorder of heme biosynthesis caused by a partial deficiency of ferrochelatase (FECH, EC 4.99.1.1). EPP is transmitted as an autosomal dominant disorder with an incomplete penetrance. Using haplotype segregation analysis, we have identified an intronic single nucleotide polymorphism (SNP), IVS3-48T/C, that modulates the use of a constitutive aberrant acceptor splice site. The aberrantly spliced mRNA is degraded by a nonsense-mediated decay mechanism (NMD), producing a decreased steady-state level of mRNA and the additional FECH enzyme deficiency necessary for EPP phenotypic expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753383     DOI: 10.1038/ng809

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  53 in total

1.  The diagnosis and management of erythropoietic protoporphyria.

Authors:  Manish Thapar; Herbert L Bonkovsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

2.  The low expression allele (IVS3-48C) of the ferrochelatase gene leads to low enzyme activity associated with erythropoietic protoporphyria.

Authors:  Tsuyoshi Tahara; Masayoshi Yamamoto; Reiko Akagi; Hideo Harigae; Shigeru Taketani
Journal:  Int J Hematol       Date:  2010-12-04       Impact factor: 2.490

Review 3.  Porphyrias at a glance: diagnosis and treatment.

Authors:  Maria Domenica Cappellini; Valentina Brancaleoni; Giovanna Graziadei; Dario Tavazzi; Elena Di Pierro
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

4.  Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria.

Authors:  John Phillips; Collin Farrell; Yongming Wang; Ashwani K Singal; Karl Anderson; Manisha Balwani; Montgomery Bissell; Herbert Bonkovsky; Toni Seay; Barry Paw; Robert Desnick; Joseph Bloomer
Journal:  Mol Genet Metab       Date:  2018-10-22       Impact factor: 4.797

5.  Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria.

Authors:  Vincent Oustric; Hana Manceau; Sarah Ducamp; Rima Soaid; Zoubida Karim; Caroline Schmitt; Arienne Mirmiran; Katell Peoc'h; Bernard Grandchamp; Carole Beaumont; Said Lyoumi; François Moreau-Gaudry; Véronique Guyonnet-Dupérat; Hubert de Verneuil; Joëlle Marie; Herve Puy; Jean-Charles Deybach; Laurent Gouya
Journal:  Am J Hum Genet       Date:  2014-03-27       Impact factor: 11.025

Review 6.  [Hereditary photodermatoses].

Authors:  P Poblete-Gutiérrez; W H C Burgdorf; C Has; M Berneburg; J Frank
Journal:  Hautarzt       Date:  2006-12       Impact factor: 0.751

Review 7.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 8.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Gut       Date:  2007-03-14       Impact factor: 23.059

9.  Paralytic ileus and liver failure--an unusual presentation of advanced erythropoietic protoporphyria.

Authors:  Simone Negrini; Gabriele Zoppoli; Maurizio Setti; Maria Domenica Cappellini; Francesco Indiveri
Journal:  Dig Dis Sci       Date:  2008-11-14       Impact factor: 3.199

Review 10.  Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.

Authors:  Manisha Balwani
Journal:  Mol Genet Metab       Date:  2019-01-24       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.